文献速递淋巴瘤

IRAK4抑制剂阻断Toll样受体信号并增敏慢性淋巴细胞白血病细胞凋亡

Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis.
PubMed 文献 · Br J Haematol · 2020-02-14

慢性淋巴细胞白血病(CLL)细胞受微环境信号驱动,体外用TLR9配体CpG刺激可诱导代谢活化并抗凋亡。临床前研究显示,IRAK4抑制剂可破坏TLR信号、降低NFKBIZ和IL-6 mRNA、诱导p53并触发凋亡,且与依鲁替尼协同。

要点

  • IRAK4在CLL患者中表达,低mRNA水平与更好结局相关
  • IRAK4抑制剂破坏TLR信号并削弱CpG对CLL细胞的保护
  • IRAK4抑制剂与依鲁替尼联用显示协同效应

核心结论

  • 靶向IRAK4可能成为CLL治疗新策略,并可与其他信号抑制剂联用。

研究设计与样本

  • 临床前研究,使用从CLL患者外周血分离的原代白血病细胞测试特异性IRAK4小分子抑制剂。

主要发现

  • IRAK4在CLL患者中表达,且较低IRAK4 mRNA水平与更好结局相关。
  • IRAK4抑制剂降低NFKBIZ和IL-6 mRNA,破坏TLR信号,并削弱体外TLR刺激对细胞活力的保护作用。
  • IRAK4抑制剂诱导p53并触发凋亡。
  • IRAK4抑制剂与递增浓度依鲁替尼共处理CLL细胞显示协同效应。

临床怎么用

  • 提示IRAK4抑制剂单药或与BTK抑制剂联用可能用于CLL,但尚需临床验证。

局限性

  • 研究为临床前体外实验,未提供临床疗效或安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukaemia (CLL) cells are strongly influenced by microenvironmental signals through the activation of distinct membrane receptors including the B-cell receptor and toll-like receptors (TLR). Recapitulating TLR stimulation in vitro by treating CLL cells with the TLR9 ligand CpG can induce metabolic activation and protection from apoptosis. We hypothesized that interfering with TLR signalling may be beneficial for treating CLL, and we tested in preclinical studies the effect of a specific interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitory small molecule on primary leukaemic cells isolated from the peripheral blood of patients. We observed that IRAK4, an upstream kinase of the TLR pathway, is expressed in patients with CLL, and lower IRAK4 mRNA levels associate with a better outcome. The specific IRAK4 inhibitor disrupted TLR signalling as assessed by reduction of the specific biomarkers NFKBIZ and interleukin-6 mRNAs, and restrained the protective effect of in vitro TLR stimulation on cell viability. To note, IRAK4 inhibitor induced p53 and triggered apoptosis. Co-treatment of CLL cells with increasing concentrations of IRAK4i and the Bruton tyrosine kinase inhibitor ibrutinib demonstrated a synergistic effect. Our results suggest that targetting IRAK4 may represent a novel approach in CLL and may be combined with other signalling inhibitors.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Delvecchio VS, Sana I, Mantione ME, et al. Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis. Br J Haematol. 2020. PMID: 32057093. doi:10.1111/bjh.16386

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。